BORDEAUX, France & BOSTON–(BUSINESS WIRE)–Regulatory News:
IMPLANET (Euronext Growth: ALIMP, FR0010458729, eligible for
PEA-PME equity savings plans) (Paris:ALIMP) (OTCQX:IMPZY), a medical
technology company specializing in vertebral and knee-surgery implants,
informs its shareholders that its Ordinary General Meeting was held on
Tuesday 11 June at 2 p.m. at the company’s registered office in
All the resolutions of the Ordinary General Meeting have been adopted.
However, the Extraordinary General Shareholders’ Meeting could not
validly deliberate due to lack of quorum. A new Extraordinary General
Shareholders’ Meeting has been called to deliberate on the same agenda
and will be held on June 25, 2019 at 02:00 pm at the Company’s
registered office, located Allée F. Magendie – Technopole Bordeaux
Montesquieu – 33650 Martillac – France.
A notice of the second meeting will be published on June 14, 2019 in the
BALO and posted on Implanet’s website.
Implanet’s shareholders’s participation is decisive to obtain the
quorum necessary to hold this Extraordinary General Meeting and vote on
the company’s resolutions.
The vote of shareholders who voted by absentee voting at the first
General Meeting remains valid and counted for the Extraordinary General
Meeting on second notice.
The shareholders can vote:
by internet via the Votaccess service (reopened on
- by absentee voting,
- by proxy voting,
- or attend physically the General Meeting
A guide contained in a Letter To Shareholders – May, 2019 outlines how
to vote, and in particular how to vote from your internet banking
interface (only in French). You can download it here.
It was also posted on Implanet’s website. The shareholders can also
contact the Investor Relations team by email for any question concerning
the ways of voting: [email protected]
The documents related to the General Meeting are available on request
from Implanet, or can be consulted on the Company’s website (https://www.Implanet-invest.com/assemblee-generale).
Founded in 2007, Implanet is a medical
technology company that manufactures high-quality implants for
orthopedic surgery. Its flagship product, the Jazz® latest-generation
implant, aims to treat spinal pathologies requiring vertebral fusion
surgery Implanet’s tried-and-tested orthopedic platform, which is based
on perfect control over the traceability of its products, provides it
with a proven ability to promote this innovation. Protected by four
families of international patents, JAZZ® has obtained 510(k) regulatory
clearance from the Food and Drug Administration (FDA) in the United
States and the CE mark and the Anvisa authorization in Brazil. Implanet
employs 38 staff and recorded 2018 sales of €6.7 million. For further
information, please visit www.Implanet.com.
Based near Bordeaux in France, Implanet established a US subsidiary in
Boston in 2013. Implanet is listed on Euronext™ Growth market in Paris.
The Company would like to remind that the table for monitoring the
equity line (BEOCABSA, OCA, BSA) and the number of shares outstanding,
is available on its website: http://www.implanet-invest.com/suivi-des-actions-80
Ludovic Lastennet, Directeur Général
Dieumegard, Directeur Financier
Tél. : 05 57 99 55 55
: 01 44 71 94 94
Tél. : 01 44 71